The firm is now inking revenue-generating contracts with other biotech companies for its drug response prediction and gene expression analysis capabilities.

That Thursday, for the first time, the European Medicines Agency (EMA) approved a drug that targets the cause — not just the ...

The decision in Europe follows an approval granted by the US Food and Drug Administration (FDA) in March this year.

In the wake of a market pull in obesity nearly five years ago, the other shoe has dropped for Eisai’s serotonin 2C receptor ...

Using cerebrospinal fluid from living patients, researchers have identified specific proteins and genetic pathways involved ...

This is a news collection page for Canberra. Check this page for latest news headlines covering major stories, events from Canberra and surrounding ACT. Get breaking news faster than any other ...

The European Medicines Agency re-examined clinical data of a subset of patients with one or no copies of the APOE4 gene ...

Reversing an earlier decision, European regulators recommended that the Alzheimer’s therapy Leqembi should be approved ...

Now, it's up to the European Commission to confirm those potential green lights in the coming weeks and months.

Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys ...

A European regulatory committee now recommends approval of the Alzheimer’s treatment lecanemab a few months after rejecting ...

Eisai Co., Ltd. (ESALF.PK) and Biogen Inc. (BIIB) announced a positive opinion has been received from the Committee for Medicinal ...